Peptide therapeutics companies develop medicines built from short chains of amino acids designed to interact with specific biological targets. These molecules can combine high target selectivity with formats suited to a wide range of therapeutic applications.
This category includes companies working on:
Browse 41 UK peptide therapeutics companies below.
Preventing cancer therapy side effects with topical medicines
VasoDynamics is a clinical-stage pharmaceutical development company focused on preventing the debilitating side effects of cancer therapy. The company develops topical formulations targeting radiation-induced oral mucositis, dermatitis, and chemotherapy-induced hair loss, using vasoconstrictor and radioprotective…
Oral and injectable peptide therapies for obesity and cardiometabolic disease
Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders. Its pipeline centres on rationally engineered peptide candidates acting on GLP-1 and amylin receptors, advanced through a proprietary oral absorption technology…
Chemical reagents and contract manufacturing for pharma and diagnostics supply chains
Biosynth Limited is the UK manufacturing and research entity of Biosynth, a global life sciences reagents and contract development and manufacturing organisation. Its Compton, Berkshire site specialises in complex chemical synthesis including carbohydrates, nucleosides, and enzyme substrates, supplying critical raw…
Oncology biotech developing peptide therapeutics and diagnostics
ValiRx is a UK-listed biopharmaceutical company focused on the development of oncology therapeutics and companion diagnostics. The company selects and incubates novel drug candidates, including peptide-based compounds targeting prostate cancer, endometriosis, and other solid tumours, progressing them from preclinical…
Peptide discovery platform targeting cell-surface therapeutic targets
Orbit Discovery is a drug discovery company providing peptide lead identification services using a proprietary bead-based peptide display engine combined with microfluidic functional screening. The platform screens libraries of over one billion natural and non-natural peptides against challenging cell-surface targets,…
Blue-mussel-derived bioactive peptide therapy for veterinary research
N2 Pharmaceuticals develops N2-01, an injectable mixture of bioactive peptides and amino acids derived from blue mussels. Its research focuses on endothelial dysfunction and vascular permeability, with potential applications in veterinary medicine and human disease. The company reports historic veterinary use in…
Topical peptide therapeutics targeting inflammatory skin disease
Carocell Bio is a pre-clinical stage biotechnology company developing proprietary peptide-based therapeutics for inflammatory diseases. Its pipeline centres on topical formulations that inhibit mitogen-activated protein kinase (MAPK/p38), a key regulator of the inflammatory cascade. Lead programmes target atopic…
TSG-6 protein therapeutics for inflammatory and degenerative disease
Link Biologics is a preclinical-stage biotechnology company developing protein therapeutics based on TSG-6, an endogenous human protein with anti-inflammatory and tissue-protective properties. Spun out from the University of Manchester in 2021, the company is advancing its lead asset, Link_TSG6, across programmes in…
Custom peptide synthesis, antibodies, and protein analysis services
Alta Bioscience is a manufacturer and accredited analytical laboratory specialising in custom biochemical synthesis and protein analysis services. The company produces custom peptides, peptide libraries, DNA oligonucleotides, and polyclonal and monoclonal antibodies for academic, pharmaceutical, and food industry…
Translational CRO offering oncology and women's health assay services
Inaphaea BioLabs is a translational contract research organisation based at MediCity Nottingham, offering cell-based assays and patient-derived cell (PDC) models to support early-stage drug discovery and preclinical development. The company specialises in oncology and women's health, providing biochemical and…
Tumour-activated peptide drug conjugates for targeted oncology
Avacta Therapeutics is a clinical-stage biotechnology company developing peptide drug conjugates designed to deliver toxic chemotherapy payloads selectively within the tumour microenvironment. The company's delivery approach uses a short engineered peptide that masks the active payload until it is cleaved by…
Novel peptide-based therapeutics and biomarkers for neurodegeneration
Neuro-Bio is a preclinical-stage biotechnology company developing a first-in-class therapeutic approach to Alzheimer's disease and related neurodegenerative disorders. Its research centres on T14, a 14 amino acid bioactive peptide derived from acetylcholinesterase, which the company has identified as a potential…
Integrated drug discovery CRO from target to clinical candidate
Sygnature Discovery is a UK-headquartered integrated drug discovery contract research organisation. Operating from sites in Nottingham, Alderley Park, and Glasgow, the company provides end-to-end drug discovery services spanning target identification, medicinal chemistry, in vitro bioscience, structural biology,…
Therapeutic cancer vaccines based on recombinant overlapping peptide technology
Oxford Vacmedix is a clinical-stage biopharma company developing therapeutic cancer vaccines using its proprietary Recombinant Overlapping Peptide (ROP) platform. ROPs stimulate broad T cell and antibody immunity without HLA restriction, enabling a universal immunotherapy approach. The lead programme, OVM-200, targets…
Integrated chemistry and development CRO for small molecules
CatSci is a Cardiff-headquartered contract research organisation providing integrated chemistry, analytical, and development services to biotech and pharmaceutical companies. Founded in 2010 by former AstraZeneca scientists, the company offers process chemistry, analytical development, solid-state and preformulation…
Peptide immunotherapies for the treatment of food allergy
Aravax is a clinical-stage biotechnology company developing next-generation specific immunotherapies for food allergy. Its lead candidate, PVX108, is a synthetic peptide-based therapy designed to desensitise peanut-allergic patients by targeting the T cells that drive allergic responses, without triggering acute…
Novel peptide therapeutics targeting obesity and type 2 diabetes
Dia Beta Labs is a preclinical-stage biotechnology company developing first-in-class therapeutic peptides for metabolic disease. Spun out of the Diabetes Research Group at Ulster University, the company is advancing three peptide candidates that act on hormone receptors to preserve insulin-producing pancreatic…
Synthetic T cell-priming vaccines and immunotherapies for infectious disease
Gylden Pharma is a clinical-stage biotechnology company developing 100% synthetic T cell-priming vaccines and immunotherapies. Its nanoparticle platform delivers synthetic peptides that stimulate cellular immune responses against intracellular pathogens, providing strain-agnostic protection without cold-chain…
Whole genome synthesis platform engineering novel therapeutic biomolecules
Constructive Bio is a Cambridge-based synthetic biology company developing programmable biology platforms for the creation of novel biomolecules. Spun out of the MRC Laboratory of Molecular Biology, the company's technology combines whole genome synthesis and engineered protein translation to produce molecules…
Engineered hybrid interferon therapeutics for viral and immune-mediated disease
ILC Therapeutics is a pre-clinical biotechnology company developing hybrid interferons, an engineered cytokine drug class combining favourable attributes of multiple naturally occurring interferon subtypes. The platform rationally designs novel candidates with reduced toxicity and pleiotropic activity across multiple…